ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pfizer, Myovant begin dosing in relugolix contraceptive study
April 15, 2021Pfizer and Myovant have announced that dosing has begun in a Phase III study evaluating the contraceptive efficacy of their relugolix combination tablet. -
Relugolix shows potential long-term benefit in women with uterine fibroids
March 26, 2021Pfizer and Myovant Sciences have announced that relugolix combination therapy could have ‘potential benefit’ for the long-term treatment of women with uterine fibroids. -
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 20, 2019Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids.
Pharma Sources Insight January 2025
